ATAI options granted, including 103,000 at $4.48; Psytech deal closes
Rhea-AI Filing Summary
Atai Beckley N.V. (ATAI) reported insider activity on November 5, 2025. A director received several stock option grants: three fully vested options at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 common shares with expirations from July 2025 to October 2032, and an additional 103,000 options at $4.48 expiring in November 2035 that vest on the first anniversary of the grant date.
On the same date, the company completed its acquisition of Beckley Psytech Limited, issuing 103,000,066 common shares as consideration or as underlying replacement awards pursuant to the purchase agreement.
Positive
- None.
Negative
- None.
Insights
Large share issuance for acquisition; option grants mostly time-based.
ATAI closed the Beckley Psytech acquisition on Nov 5, 2025, issuing 103,000,066 common shares as consideration or underlying replacement awards. This is a significant equity-based transaction that increases the share count and reflects stock-settled deal mechanics.
Insider compensation disclosed the same day includes stock options: three grants at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 shares, each fully vested at grant, expiring between 2030 and 2032; plus 103,000 options at $4.48 expiring in 2035, vesting on the first anniversary. These are standard time‑based awards.
Potential effects depend on post-close integration and future disclosures. Actual dilution impact follows from the 103,000,066-share issuance; option exercises depend on market price versus the $1.35 and $4.48 strikes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 456,011 | $0.00 | -- |
| Grant/Award | Stock Option | 97,716 | $0.00 | -- |
| Grant/Award | Stock Option | 62,394 | $0.00 | -- |
| Grant/Award | Stock Option | 103,000 | $0.00 | -- |
Footnotes (1)
- On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement. The stock option is fully vested as of the grant date. The stock option shall vest in full on the first anniversary of the grant date.